You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Breast cancer

Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

  • Technology appraisal guidance
  • Reference number: TA810
  • Published:  20 July 2022
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

On this page

  1. Resource impact
  2. Guidance into practice

Tools and resources

Tools and resources to help you put the guidance into practice.

Resource impact

  • Resource impact template (Excel 1.24 MB)

    Published:
    20 July 2022
  • Resource impact report (PDF 210 KB)

    Published:
    20 July 2022

Guidance into practice

  • About the Into practice guide

  • Practical steps to improving the quality of care and services using NICE guidance

Back to top